Here are the DEF 14A proxy statements from ADC Therapeutics SA (ADCT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
ADC Therapeutics is calling a virtual 2026 annual meeting on June 1, 2026 to vote on governance, compensation and capital matters. Shareholders of record on April 16, 2026, when 127,189,572 common shares were outstanding, may participate and vote online.
Key proposals include approving 2025 financial statements, the Swiss and U.S. compensation reports, discharging directors and executives from liability, carrying forward the 2025 loss, and reelecting directors, compensation committee members, the independent proxy and auditors. Shareholders will also vote on director and executive pay, an increase to the 2019 Equity Incentive Plan share authorization, and amendments to expand the company’s capital range and conditional share capital. The board recommends voting FOR all items.
The proxy also details 2025 pay practices. Corporate goals under the annual incentive plan were achieved at 125%, driven by $73.6 million in Zynlonta net sales, progress in clinical programs, restructuring to focus on Zynlonta, and financings that extended the expected cash runway into at least mid‑2028. This resulted in bonuses of $582,063 for CEO Ameet Mallik, $328,255 for CFO Jose Carmona and $431,325 for CMO Mohamed Zaki. Long‑term incentives were delivered mainly as time‑vested RSUs with double‑trigger change‑in‑control protection, and the company maintains a clawback policy and restrictions on hedging and pledging.